CurrentCardio
Get Weekly

Topic · page 5 of 6

Cardiometabolic & kidney

Diabetes, obesity, CKD and their cardiovascular or cardiorenal outcomes, SGLT2i/GLP-1 RA outside a primary HF population

Briefs 161–200 of 238 placed here, newest publication first

Briefs in Cardiometabolic & kidney

Newest publication first

  1. J Am Coll Cardiol

    Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults

    Cohort study

  2. Nat Med

    Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial

    Randomised controlled trial

  3. Eur J Prev Cardiol

    Circadian heart rate fluctuations predict cardiovascular and all-cause mortality in type 2 and type 1 diabetes: a 21-year retrospective longitudinal study

    Secondary analysis

  4. J Am Coll Cardiol

    Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review

    Research article

  5. Eur J Heart Fail

    Development and Validation of a Machine Learning-Based Approach to Identify High-Risk Diabetic Cardiomyopathy Phenotype

    Diagnostic or prognostic study

  6. Eur J Prev Cardiol

    The reduction of the productivity burden of cardiovascular disease by improving the risk factor control Among Australians with type 2 diabetes: a 10-year dynamic analysis

    Research article

  7. J Am Coll Cardiol

    Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM

    Cohort study

  8. Nat Med

    Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

    Meta-analysis

  9. Eur J Prev Cardiol

    Obesity and cardiovascular disease: an ESC clinical consensus statement

    Guideline or statement

  10. J Am Coll Cardiol

    Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

    Secondary analysis

  11. Circulation

    Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Meta-analysis

  12. Eur Heart J

    Obesity and cardiovascular disease: an ESC clinical consensus statement

    Guideline or statement

  13. Circulation

    Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation

    Cohort study

  14. J Am Coll Cardiol

    Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes

    Cohort study

  15. Circulation

    Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial

    Randomised controlled trial

  16. JACC Cardiovasc Imaging

    The Impact of Bariatric Surgery on Coronary Microvascular Function Assessed Using Automated Quantitative Perfusion CMR

    Cohort study

  17. J Am Coll Cardiol

    Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes

    Randomised controlled trial

  18. Circulation

    Loss of Y Chromosome and Cardiovascular Events in Chronic Kidney Disease

    Cohort study

  19. Eur J Prev Cardiol

    Associations of uric acid with the risk of cardiovascular disease and all-cause mortality among individuals with chronic kidney disease: the Kailuan Study

    Cohort study

  20. Eur J Prev Cardiol

    Differences in the association of lifestyle-related modifiable risk factors with incident cardiovascular disease between individuals with and without diabetes

    Cohort study

  21. Circulation

    Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial

    Secondary analysis

  22. Eur J Heart Fail

    Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial

    Meta-analysis

  23. J Am Coll Cardiol

    Adverse Cardiovascular Outcomes in Patients With Obstructive Sleep Apnea and Obesity: Metabolic Surgery vs Usual Care

    Cohort study

  24. Europace

    Chronic kidney disease and transvenous cardiac implantable electronic device infection—is there an impact on healthcare utilization, costs, disease progression, and mortality?

    Cohort study

  25. Eur J Prev Cardiol

    Exposure to workplace sexual harassment and risk of cardiometabolic disease: a prospective cohort study of 88 904 Swedish men and women

    Cohort study

  26. JAMA

    Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020

    Cross-sectional study

  27. JAMA Cardiol

    Deep Learning–Based Assessment of Built Environment From Satellite Images and Cardiometabolic Disease Prevalence

    Cross-sectional study

  28. Nat Med

    IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

    Randomised controlled trial

  29. Nat Med

    Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

    Secondary analysis

  30. Circulation

    Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association

    Guideline or statement

  31. Nat Med

    Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure

    Cohort study

  32. Nat Med

    Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

    Secondary analysis

  33. Eur Heart J

    Income variability and incident cardiovascular disease in diabetes: a population-based cohort study

    Cohort study

  34. Eur J Prev Cardiol

    The role of exercise training on cardiovascular risk factors and heart disease in patients with chronic kidney disease G3–G5 and G5D: a Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the European Association of Rehabilitation in Chronic Kidney Disease

    Guideline or statement

  35. Eur J Prev Cardiol

    Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model

    Diagnostic or prognostic study

  36. Eur J Prev Cardiol

    The relationship between processed meat, red meat, and risk of cardiovascular disease and Type 2 diabetes: a Mendelian randomization study

    Research article

  37. Eur J Prev Cardiol

    Association between cumulative metabolic risk exposure and cardiovascular disease: a nationwide cohort of over 3.6 million young adults

    Cohort study

  38. Eur J Prev Cardiol

    Interaction between type 2 diabetes polygenic risk and physical activity on cardiovascular outcomes

    Cohort study

  39. J Am Coll Cardiol

    Vascular Regenerative Cell Deficiencies in South Asian Adults

    Cohort study

  40. BMJ

    Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study

    Cohort study

All 238 Briefs in ExploreShowing Briefs 161–200 of 238, newest first